United Health Products has made significant strides in its regulatory and market positioning efforts, submitting critical documentation for FDA device approval and potential OTCQB market uplisting. The medical technology company has completed additional safety testing for its CelluSTAT Hemostatic Gauze, a product designed to control mild to moderate bleeding.
The FDA previously requested supplemental sterilization and biotoxicity tests for the company's Investigational Device Exemption (IDE) application. The newly submitted test results confirm that the hemostatic gauze meets safety requirements for a Class III, absorbable medical device. This development is crucial for advancing the company's clinical study, which aims to enroll 27 patients.
Simultaneously, United Health Products has responded to OTC Markets' information request regarding its application to be quoted on the OTCQB market. The submission of the additional requested materials allows OTC Markets to proceed with its review of the uplisting application.
While the company cannot guarantee approval for either the FDA Premarket Approval or the OTCQB uplisting, these steps represent important progress in United Health Products' strategic objectives. The potential FDA approval would provide access to the human surgical market, while the OTCQB uplisting could enhance the company's market visibility and investor accessibility.
The CelluSTAT Hemostatic Gauze, an all-natural product, represents an innovative approach to managing bleeding in medical settings. The company's continued regulatory efforts underscore its commitment to bringing this technology to market and meeting rigorous safety standards.
